UIC-2019-103 Method of Use of Mitogen Activated Protein Kinase Kinase (MEK) Inhibitors

Use of Mitogen Activated Protein Kinase Kinase (MEK) inhibitors to treat congenital aniridia: Improves ocular morphology and development. Reduces corneal stromal thickness, scar area, and opacity. Increases ocular function and response to light stimulation. Observed via electroretinography. Effective in both oral and topical formulations. Preliminary evidence indicates that the formulated MEK inhibitor is soluble in poloxamers. Jonathan Gortat jgortat@otm.uic.edu (312) 413-1643

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More